Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|November 21, 2019
Anti-Microbial Resistance and the Role of Vaccines
Author(s)SGS
This webcast will look at the scale of AMR, how CROs can assist in the development plan of new antimicrobials and where commercial development of new vaccines may be most effective. It will also provide insights and expert opinion on the potential success of antibacterial vaccination in controlling the rise of AMR and reducing the economic burden of infectious diseases. Live: North America: Thursday, Nov. 21, 2019 at 11am EST | 10am CST | 8am PST On demand available after airing until Nov. 21, 2020. Register free
Register free:
Event Overview:
The prospect of widespread antimicrobial resistance in the global community offers a world view where AMR takes us “…back to the dark ages of medicine” (D.Cameron,2014). Although there are global initiatives looking to promote better prescribing practice, to encourage innovative approaches to reversing AMR or to assist in the development of new classes of antibiotics, the role of vaccination in controlling community carriage and spread of AMR strains is sometimes overlooked. This webinar will examine at the scale of AMR, how CROs can assist in the development plan of new antimicrobials and where commercial development of new vaccines may be most effective. It will also provide insights and expert opinion on the potential success of antibacterial vaccination in controlling the rise of AMR and reducing the economic burden of infectious diseases.
Key Learning Objectives:
- The geographic spread of AMR and global threat to health, and its impact on prosperity
- The scope of AMR interventions currently in operation and the roles of academia and commercial organizations (e.g., CROs) within them
- Current antibacterial vaccines – successes and failures – hope for the future?
- New approaches and targets in AMR control
- Rolling out AMR vaccines – hurdles and barriers to success
Speakers: Professor Adam Cunningham, Professor of Functional Immunity at Institute of Immunology and Immunotherapy, Birmingham, UK
Adrian Wildfire, Scientific Director, SGS Life Sciences
Time and date: North America: Thursday, Nov. 21, 2019 at 11am EST | 10am CST | 8am PST
On demand available after airing until Nov. 21, 2020.
Sponsor: SGS
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5